{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:09Z","timestamp":1793045469414,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274260"],"award-info":[{"award-number":["82274260"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2015020305"],"award-info":[{"award-number":["2015020305"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02642-9","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:59:56Z","timestamp":1738907996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of hepatic steatosis on the efficacy of antiviral treatment for chronic hepatitis B and the establishment of predictive model: a cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Guanghui","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaining","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2642_CR1","unstructured":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879\u2013907."},{"key":"2642_CR2","unstructured":"WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. July 18, 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240053779. Accessed 3 Aug 2022."},{"key":"2642_CR3","doi-asserted-by":"crossref","unstructured":"Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4).","DOI":"10.3390\/v9040075"},{"key":"2642_CR4","unstructured":"The expert consensus on clinical cure (functional cure) of chronic hepatitis B. J Clin Hepatobil Dis. 2019, 35(08):1693\u20131701."},{"issue":"9","key":"2642_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691\u2013700.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2642_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12985-023-02277-8","volume":"21","author":"S Yi","year":"2024","unstructured":"Yi S, Ren G, Zhu Y, Cong Q. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study. Virol J. 2024;21(1):22.","journal-title":"Virol J"},{"issue":"4","key":"2642_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u20136.","journal-title":"J Hepatol"},{"issue":"5","key":"2642_CR8","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.15(5)2015.27909","volume":"15","author":"RN Zhang","year":"2015","unstructured":"Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15(5): e27909.","journal-title":"Hepat Mon"},{"issue":"6","key":"2642_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11262-023-02028-5","volume":"59","author":"X Du","year":"2023","unstructured":"Du X, Shi X, Han M, Gao X, Wang C, Jiang C, et al. SCD1 inhibits HBV replication by regulating autophagy under high lipid conditions. Virus Genes. 2023;59(6):801\u201316.","journal-title":"Virus Genes"},{"issue":"Suppl 1","key":"2642_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/liv.12403","volume":"34","author":"M Martinot-Peignoux","year":"2014","unstructured":"Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34(Suppl 1):97\u2013107.","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"2642_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12072-009-9149-7","volume":"3","author":"T Nguyen","year":"2009","unstructured":"Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3(Suppl 1):5\u201315.","journal-title":"Hepatol Int"},{"key":"2642_CR12","unstructured":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403."},{"key":"2642_CR13","unstructured":"Chinese Medical Association Hepatology Branch, Chinese Medical Association Infectious Disease Branch. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Pract Liver Dis. 2023, 26(3):1\u201322"},{"issue":"04","key":"2642_CR14","first-page":"494","volume":"27","author":"F Jiangao","year":"2024","unstructured":"Jiangao F, Xiaoyuan X, Yuemin N, Lai W, Jidong J, Hui Z, et al. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024). J Pract Liver Dis. 2024;27(04):494\u2013510.","journal-title":"J Pract Liver Dis."},{"issue":"7","key":"2642_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/jvh.13942","volume":"31","author":"F Rui","year":"2024","unstructured":"Rui F, Garcia E, Hu X, Ni W, Xue Q, Xu Y, et al. Antiviral therapy response in patients with chronic hepatitis B and fatty liver: a systematic review and meta-analysis. J Viral Hepat. 2024;31(7):372\u201382.","journal-title":"J Viral Hepat"},{"issue":"4","key":"2642_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.23844","volume":"52","author":"MJ Sonneveld","year":"2010","unstructured":"Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251\u20137.","journal-title":"Hepatology"},{"issue":"10","key":"2642_CR17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, et al. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat. 2019;26(10):1146\u201355.","journal-title":"J Viral Hepat"},{"key":"2642_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.intimp.2018.06.043","volume":"62","author":"N Liu","year":"2018","unstructured":"Liu N, Liu B, Zhang L, Li H, Chen Z, Luo A, et al. Recovery of circulating CD56(dim) NK cells and the balance of Th17\/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg. Int Immunopharmacol. 2018;62:59\u201366.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2642_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/cei.13486","volume":"202","author":"X Pang","year":"2020","unstructured":"Pang X, Zhang L, Liu N, Liu B, Chen Z, Li H, et al. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients. Clin Exp Immunol. 2020;202(1):80\u201392.","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"2642_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/jvh.13114","volume":"26","author":"WJ Jeng","year":"2019","unstructured":"Jeng WJ, Chang ML, Liaw YF. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. J Viral Hepat. 2019;26(8):1019\u201326.","journal-title":"J Viral Hepat"},{"issue":"8","key":"2642_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325\u201332.","journal-title":"Gut"},{"issue":"08","key":"2642_CR22","first-page":"1693","volume":"35","author":"Chinese Society of Infectious DiseaseChinese Society of Hepatology","year":"2019","unstructured":"Chinese Society of Infectious DiseaseChinese Society of Hepatology. Chinese Medical Association The expert consensus on clinical cure (functional cure) of chronic hepatitis B. J Clin Hepatobil Dis. 2019;35(08):1693\u2013701.","journal-title":"J Clin Hepatobil Dis."},{"issue":"6","key":"2642_CR23","doi-asserted-by":"publisher","first-page":"E1032","DOI":"10.1152\/ajpendo.00518.2020","volume":"320","author":"D Xie","year":"2021","unstructured":"Xie D, Zhao H, Lu J, He F, Liu W, Yu W, et al. High uric acid induces liver fat accumulation via ROS\/JNK\/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320(6):E1032\u201343.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"2642_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14899","volume":"75","author":"F Bacaks\u0131z","year":"2021","unstructured":"Bacaks\u0131z F, G\u00f6kcan H, Akdo\u011fan M, G\u00f6k\u00e7e DT, Ar\u0131 D, G\u00f6kbulut V, et al. Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients. Int J Clin Pract. 2021;75(12): e14899.","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2642_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/hep.32792","volume":"77","author":"X Mao","year":"2023","unstructured":"Mao X, Cheung KS, Peng C, Mak LY, Cheng HM, Fung J, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology. 2023;77(5):1735\u201345.","journal-title":"Hepatology"},{"issue":"3","key":"2642_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","volume":"22","author":"SC Huang","year":"2024","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion. Clin Gastroenterol Hepatol. 2024;22(3):581-90 e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2642_CR27","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s11010-021-04143-z","volume":"477","author":"Q Liu","year":"2022","unstructured":"Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu J, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477(11):2481\u201391.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"2642_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/liv.14369","volume":"40","author":"J Zhang","year":"2020","unstructured":"Zhang J, Lin S, Jiang D, Li M, Chen Y, Li J, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors? Liver Int. 2020;40(3):496\u2013508.","journal-title":"Liver Int"},{"issue":"7","key":"2642_CR29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3748\/wjg.v13.i7.1060","volume":"13","author":"XJ Ma","year":"2007","unstructured":"Ma XJ, Tian DY, Xu D, Yang DF, Zhu HF, Liang ZH, et al. Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice. World J Gastroenterol. 2007;13(7):1060\u20136.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2642_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5): 100350.","journal-title":"JHEP Rep"},{"issue":"10","key":"2642_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29156","volume":"95","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen S, Wu X, Zhou J, Wang T, Liu H, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. J Med Virol. 2023;95(10): e29156.","journal-title":"J Med Virol"},{"issue":"1","key":"2642_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jvh.12766","volume":"25","author":"RWH Hui","year":"2018","unstructured":"Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25(1):97\u2013104.","journal-title":"J Viral Hepat"},{"issue":"10","key":"2642_CR33","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1111\/liv.16032","volume":"44","author":"HS Kim","year":"2024","unstructured":"Kim HS, Kim JS, Kim JM, Han JW, Lee SK, Nam H, et al. Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg. Liver Int. 2024;44(10):2753\u201362.","journal-title":"Liver Int"},{"issue":"4","key":"2642_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100664","volume":"5","author":"A Aggarwal","year":"2023","unstructured":"Aggarwal A, Odorizzi PM, Brodbeck J, van Buuren N, Moon C, Chang S, et al. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Rep. 2023;5(4): 100664.","journal-title":"JHEP Rep"},{"key":"2642_CR35","doi-asserted-by":"publisher","first-page":"1243202","DOI":"10.3389\/fmed.2023.1243202","volume":"10","author":"K Song","year":"2023","unstructured":"Song K, Zeng D, Zheng Y, Zhang H, Weng Z, Zhou Y, et al. A simple-to-use score system for predicting HBsAg clearance to peginterferon alfa-2b in nucleoside analogs-experienced chronic hepatitis B patients. Front Med (Lausanne). 2023;10:1243202.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"2642_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.clinthera.2020.12.022","volume":"43","author":"C Hu","year":"2021","unstructured":"Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: a real-world experience. Clin Ther. 2021;43(3):572-81 e3.","journal-title":"Clin Ther"},{"issue":"46","key":"2642_CR37","doi-asserted-by":"publisher","first-page":"13087","DOI":"10.3748\/wjg.v21.i46.13087","volume":"21","author":"MH Su","year":"2015","unstructured":"Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, et al. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol. 2015;21(46):13087\u201394.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2642_CR38","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126(7):1750\u20138.","journal-title":"Gastroenterology"},{"issue":"34","key":"2642_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012089","volume":"97","author":"Q Su","year":"2018","unstructured":"Su Q, Liu Y, Li J. Combined effect of pegylated interferon \u03b1 with adefovir on renal function in Chinese patients with chronic hepatitis B. Medicine (Baltimore). 2018;97(34): e12089.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2642_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jvh.12820","volume":"25","author":"ES Cannizzo","year":"2018","unstructured":"Cannizzo ES, Tincati C, Binda F, Ronzi P, Cazzaniga FA, Antinori S, et al. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: a randomized study. J Viral Hepat. 2018;25(4):381\u201390.","journal-title":"J Viral Hepat"},{"issue":"2","key":"2642_CR41","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1172\/JCI58847","volume":"122","author":"L Belloni","year":"2012","unstructured":"Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122(2):529\u201337.","journal-title":"J Clin Invest"},{"issue":"12","key":"2642_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32730","volume":"10","author":"L Wu","year":"2024","unstructured":"Wu L, Li Z, Gao N, Deng H, Zhao Q, Hu Z, et al. Interferon-\u03b1 could induce liver steatosis to promote HBsAg loss by increasing triglyceride level. Heliyon. 2024;10(12): e32730.","journal-title":"Heliyon"},{"issue":"3","key":"2642_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2(3):177\u201388.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"2642_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3851\/IMP3240","volume":"23","author":"Y Tatsukawa","year":"2018","unstructured":"Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, et al. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside\/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study. Antivir Ther. 2018;23(8):639\u201346.","journal-title":"Antivir Ther"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02642-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:00:03Z","timestamp":1738908003000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02642-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2642"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02642-9","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"2 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. Committee of the first affiliated hospital of Dalian Medical University, Approval No. PJ-KS-KY-2023\u2013339. All informed consent was obtained from the subject(s) and\/or guardian(s). Written informed consent was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}